These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22047156)

  • 21. [Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
    Wang XQ; Tong X; Tang H; Liu PP; Zhang W; Yang RG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1112-5. PubMed ID: 18396668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.
    Montes B; Segondy M
    J Med Virol; 2002 Mar; 66(3):299-303. PubMed ID: 11793380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
    Margot N; Ram R; Abram M; Haubrich R; Callebaut C
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay.
    Choi JY; Kwon OK; Choi SY; Park YK; Kim SS
    J Clin Virol; 2011 Jan; 50(1):19-25. PubMed ID: 20970373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System.
    Cheung KW; Peng Q; He L; Cai K; Jiang Q; Zhou B; To SW; Yam WC; Liu L; Chen Z; Wang H
    PLoS One; 2016; 11(4):e0153641. PubMed ID: 27092551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
    Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
    Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
    AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.
    Sarmati L; Nicastri E; Parisi SG; d'Ettorre G; Mancino G; Narciso P; Vullo V; Andreoni M
    J Clin Microbiol; 2002 Feb; 40(2):335-40. PubMed ID: 11825939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
    Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.
    Derache A; Wallis CL; Vardhanabhuti S; Bartlett J; Kumarasamy N; Katzenstein D
    J Infect Dis; 2016 Jan; 213(2):250-6. PubMed ID: 26175454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.
    Duwe S; Brunn M; Altmann D; Hamouda O; Schmidt B; Walter H; Pauli G; Kücherer C
    J Acquir Immune Defic Syndr; 2001 Mar; 26(3):266-73. PubMed ID: 11242200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. K65R, TAMs and tenofovir.
    Miller MD
    AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on HIV-1 drug resistance profile of 257 AIDS patients with failure on the first-line antiretroviral treatment in Henan].
    Liu J; Cui WG; Liu CH; Zhu XP; Dou ZH; Wu YS; Zhu Q; Wang Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Mar; 33(3):318-22. PubMed ID: 22613387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A simple and cost-saving phenotypic drug susceptibility testing of HIV-1.
    Weng Y; Zhang L; Huang J; Zhao J; Luo P; Bi S; Yang Z; Zhu H; Allain JP; Li C
    Sci Rep; 2016 Sep; 6():33559. PubMed ID: 27640883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.
    Fourati S; Malet I; Guenzel CA; Soulie C; Maidou-Peindara P; Morand-Joubert L; Wirden M; Sayon S; Peytavin G; Simon A; Katlama C; Benichou S; Calvez V; Marcelin AG
    Antiviral Res; 2012 Jan; 93(1):167-74. PubMed ID: 22138483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.